Zinc Chloride

Summary

Zinc Chloride (CHEMBL1200679) is an approved small-molecule EC 5.3.3.5 (cholestenol Δ-isomerase) inhibitor (ATC B05XA12).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B05XA12
• Chemistry: 136.3 Da · Cl2Zn

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200679
Name	Zinc Chloride
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3007855
ChEBI	CHEBI:49976
ATC	B05XA12
Molecular formula	Cl2Zn
Molecular weight	136.3
InChIKey	JIAARYAFYJHUJI-UHFFFAOYSA-L

SMILES: [Cl-].[Cl-].[Zn+2]

IUPAC name: zinc dichloride

ChEBI definition: A compound of zinc and chloride ions in the ratio 1:2. It exists in four crystalline forms, in each of which the Zn2+ ions are trigonal planar coordinated to four chloride ions.

Pharmacological roles (ChEBI): Lewis acid, disinfectant, astringent, EC 5.3.3.5 (cholestenol Δ-isomerase) inhibitor.

Also known as: NSC-529648, Zinc chloride, Zincum muriaticum, ZINC CHLORIDE, Zinc Chloride, SID144211809, zinc(II) chloride

Patent coverage: 178,496 distinct patent families (411,454 SureChEMBL compound mentions), from 2 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 8 (assay-derived). Sample: Tyrosine-protein kinase Fyn, Epidermal growth factor receptor, Carbonic anhydrase 2, Sodium-dependent noradrenaline transporter, Androgen receptor, G-protein coupled receptor 39, Ubiquitin-conjugating enzyme E2 T, Protein phosphatase 3 catalytic subunit alpha.

Bioactivity

ChEMBL activities: 9 potent at pChembl ≥ 5 of 10 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
GPR39	8.44	EC50	3.6	nM	CHEMBL_ACT_15097634
PPP3CA	5.96	IC50	1100	nM	CHEMBL_ACT_7791306
CA2	5.94	IC50	1159	nM	CHEMBL_ACT_7790348
FYN	5.73	IC50	1878	nM	CHEMBL_ACT_7791310
EGFR	5.66	IC50	2188	nM	CHEMBL_ACT_7791308
P15207	5.36	Ki	4339	nM	CHEMBL_ACT_7791349
P15207	5.19	IC50	6509	nM	CHEMBL_ACT_7791348
SLC6A2	5.16	Ki	6950	nM	CHEMBL_ACT_7790325
SLC6A2	5.15	IC50	7008	nM	CHEMBL_ACT_7790324

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).